Trial Profile
A Phase I/II Trial of DFMO in Combination With Bortezomib in Patients With Relapsed or Refractory Neuroblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Jan 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Eflornithine (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions; Therapeutic Use
- 01 Sep 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Nov 2023.
- 30 Aug 2023 Planned End Date changed from 1 Dec 2023 to 1 Feb 2024.
- 30 Aug 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Sep 2023.